GLA synergistic with gemcitabine in pancreatic cancer

Discussion in 'Health and medical' started by Roger, Jan 31, 2004.

  1. Roger

    Roger Guest

    Pancreatology. 2003;3(5):367-73; discussion 373-4. Epub 2003 Sep 24.

    Synergistic activity of gamma-linolenic acid and cytotoxic drugs against pancreatic adenocarcinoma
    cell lines.

    Whitehouse PA, Cooper AJ, Johnson CD.

    Department of Surgery, Southampton General Hospital, Southampton, UK.

    BACKGROUND: Gamma-linolenic acid (GLA) is growth inhibitory both in vitro and in vivo, at doses non-
    toxic to non-cancer cells. Chemotherapeutic agents have limited activity in pancreatic cancer.
    Interactions between GLA and cytotoxic drugs have not previously been investigated; any synergy
    might improve the therapeutic effect of these agents. AIM: To investigate possible interactions
    between GLA and 5-fluorouracil (5-FU) or gemcitabine against pancreatic cancer cell lines in vitro.

    METHODS: Two pancreatic cancer cell lines were exposed to GLA alone and in combination with 5-FU or
    gemcitabine. Residual viable biomass was measured using the MTT assay and the results analysed by
    the median effect method of Chou and Talalay [Adv Enzyme Regul 1984;22:27-55].

    RESULTS: GLA concentrations of 3.9- 125 microg/ml had a synergistic or additive growth inhibitory
    effect on all tested concentrations of gemcitabine. Synergism was demonstrated between GLA and 5-FU
    only at concentrations of 62.5-125 microg/ml of 5-FU.

    CONCLUSION: GLA has a synergistic effect with gemcitabine at concentrations that correspond to in
    vivo therapeutic doses. GLA with 5-FU is synergistic only at a tight range of high concentrations of
    5-FU. GLA lacks toxic side effects and may be useful in combination with gemcitabine. Copyright 2003
    S. Karger AG, Basel and IAP